Remove topic regulatory-authority-actions
article thumbnail

5 Things To Know About Antimicrobial Stewardship Regulatory Standards

IDStewardship

In this article an infectious diseases pharmacist with experience managing antimicrobial stewardship programs discusses antimicrobial stewardship regulatory standards Authored by: Timothy P. In 2015 a National Action Plan for Combating Antibiotic Resistant Bacteria was released, known as CARB. Gauthier, Pharm.D.,

Hospitals 236
article thumbnail

ISPE’s Regulatory Commenting Process

ISPE

ISPE’s Regulatory Commenting Process Trudy Patterson Tue, 02/14/2023 - 16:19 iSpeak Blog iSpeak ISPE’s Regulatory Commenting Process Wendy McGhee 14 February 2023 What is Commenting? ISPE’s commenting process is overseen by ISPE’s Regulatory Quality Harmonization Committee (RQHC) and managed by ISPE regulatory staff.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2022 ISPE Annual Meeting: Convergence and Harmonization Support New Therapies

ISPE

The regulatory keynote was delivered by Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research (CBER), US FDA. He discussed overcoming barriers to delivering gene therapy, the case for global regulatory convergence, timing for global education and harmonization, and practical next steps. Thu, 11/03/2022 - 13:48.

article thumbnail

Antiviral Drugs: The Unmet Requirement in the Pharmaceutical Space

Roots Analysis

Some of the mechanism of actions of these drugs are outlined below: Approved Antiviral Drugs: Current Market Landscape Close to 80 anti-viral drugs have been approved, till date, for the treatment of an array of infectious diseases; nearly 75% of these drugs are administered via oral route.

52
article thumbnail

COVID At-Home Antigen Tests: If at First You Don’t Succeed Try, Try and Try Again

The FDA Law Blog

Lewis, Senior Regulatory Device & Biologics Expert — We are almost three years into the public health emergency as a result of the COVID-19 pandemic, and still only have 19 rapid antigen tests authorized for at-home use in the United States. Baumhardt, Senior Medical Device Regulation Expert & Richard A.

article thumbnail

Building Resilient and Sustainable Pharmaceutical Supply Chains

ISPE

Global health authorities have been actively developing guidance and recommendations to mitigate disruptions in the supply chain, ensuring secure patient access to critical medicines. This session emphasizes the importance of aligning with regulatory efforts and offers expanded guidance on drug shortage prevention.

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

As digital health sits at the intersection of technical, scientific, and regulatory disciplines involving medical devices, drugs, and biologics, the successful development of novel DHTs will require significant collaboration with health care stakeholders to overcome regulatory, technical, and life-cycle management challenges.